Early CMML Treatment Data to Debut at ASH

Adults with chronic myelomonocytic leukemia will see first Phase 1 results for STX-0712 at the December 2026 meeting.

Updated on Nov. 4, 2026 in Cancer

Isometric editorial illustration of white vials in a steel tray on a laboratory bench, one holding a cloudy amber droplet, in muted cream and slate tones. — Solu Therapeutics will present initial Phase 1 results for its investigational CMML therapy STX-0712 at the American Society of Hematology meeting on December 13, 2026. AI Illustration. Upload story photo >

Solu Therapeutics has had two abstracts selected for oral presentation at the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, December 12-15, 2026. The company will present initial Phase 1 results for STX-0712 in chronic myelomonocytic leukemia (CMML) and new preclinical data on STX-0640, with the CMML presentation scheduled for December 13, 2026, which is of interest to patients and clinicians following blood cancer research in the United States.

Why it matters

The selections place early-stage data from a first-in-human study of an investigational CMML therapy in front of the hematology community ahead of any broader clinical use. For people following blood cancers, this signals a new approach being tested for a disease with limited treatment options, though the data are still early and their meaning will depend on what the full presentation shows.

The STX-0712 results come from a first-in-human Phase 1 study in patients with relapsed or refractory CMML and AML, while the STX-0640 data are preclinical. Because the CMML data are early-stage and the STX-0640 work is laboratory-based, neither should be read as evidence of clinical benefit at this point.

The players

Solu Therapeutics

A biotechnology company developing therapies that aim to eliminate disease-driving cells in cancer and immunology, including the CCR2-targeting STX-0712 and mast cell depletor STX-0640.

American Society of Hematology (ASH)

A professional society of blood specialists whose annual meeting is a major venue for presenting hematology and blood cancer research.

U.S. Food and Drug Administration

The federal agency that reviews and approves drugs and biologics and grants expedited programs such as Fast Track Designation.

GSK

A global pharmaceutical company whose research and licensing arrangements include the CyTAC platform that Solu Therapeutics has exclusively licensed.

Philip Vickers

President and CEO of Solu Therapeutics, leading the company's oncology and immunology pipeline.

The details

STX-0712 is an investigational Cytotoxicity Targeting Chimera that selectively eliminates cells expressing the CCR2 receptor, a protein found on the disease-driving cells the company is targeting. STX-0640 pairs a selective small-molecule binder of MRGPRX2 with a T cell engager, an approach intended to direct the immune system toward mast cells implicated in systemic mastocytosis and certain immuno-dermatologic diseases. The U.S. Food and Drug Administration has granted STX-0712 Fast Track Designation, a program meant to speed review of drugs addressing serious conditions with unmet need.

December 12-15, 2026: 68th ASH Annual Meeting in New Orleans, LA.
December 13, 2026 at 9:30 AM CT: STX-0712 CMML Phase 1 oral presentation.
December 13, 2026 at 5:30 PM CT: STX-0640 preclinical oral presentation.

Health Landscape

CMML is a rare blood cancer with limited approved options, and early-stage programs like STX-0712 are being developed against that gap. The FDA's Fast Track Designation is the agency's mechanism for accelerating development of candidates in such areas, so this designation signals regulatory interest but not approval.

If you or someone you know has CMML or systemic mastocytosis, these early results are worth discussing with a hematologist, who can explain whether any investigational studies might be relevant. Because these are early-stage findings, they should not change current treatment decisions without a conversation with your physician.

The takeaway

Early-stage cancer research is often presented first at major meetings like ASH, so the December presentation is the place to see the full Phase 1 data. Anyone with a blood disorder can ask their hematologist about clinical trials that may be recruiting for CMML or related conditions.

What happens next

Solu Therapeutics' STX-0712 CMML Phase 1 results and STX-0640 preclinical data are scheduled for oral presentation at the 68th ASH Annual Meeting on December 13, 2026.